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The aryl hydrocarbon receptor (AHR) binds environmental toxins and mediates immune regulation. The tryptophan
metabolite kynurenine has now been identified as an endogenous ligand of the human AHR constitutively produced by
gliomas and other types of cancer via tryptophan-2,3-dioxygenase (TDO), thereby suppressing antitumor immune
responses via the AHR. Thus, this pathway represents an important novel target for cancer immunotherapy.
The aryl hydrocarbon receptor (AHR) is a
basic helix-loop-helix (bHLH) Per-Arnt-
Sim (PAS) family transcription factor,
which is expressed in a variety of cells
and activated by xenobiotics such as benzo
[a]pyrene and 2,3,7,8-tetrachlordibenzo-
dioxin (TCDD).
1 There is increasing
evidence that the AHR reaches far beyond
simply binding xenobiotics to induce a
metabolic machinery (cytochrome P450
oxidases) that eliminates these toxic com-
pounds from the body. The largest body of
evidence for additional functions of the
AHR, particularly regulating immune
responses, stem from in vivo studies with
TCDD, which binds and activates the
AHR but resists metabolic degradation.
For instance, treatment of mice with auto-
immune neuroinflammation with TCDD
suppresses encephalitogenic T cell respon-
ses and ameliorates disease severity.
2 The
AHR is enriched in interleukin 17 (IL-
17)-producing CD4+ T cells (TH17 cells)
and controls the differentiation of naïve
CD4+ T cells.
2,3 Its function in the con-
text of T helper cell differentiation appears
to be conferred by ligand-dependent signal
strength and duration and thus result in
the generation of regulatory T cells (Treg)
or TH17.
2,3 In addition, AHR influences
dendritic cell (DC) function.
4 Whether
the AHR is expressed in and influences the
function of CD8+ T cells is still a matter
of debate, which may be a reason why the
role of the AHR has not been explored in
the context of tumor immunity thus far.
Another reason may reside in the uncer-
tainty of an endogenous ligand activating
the AHR in the tumor micromilieu.
Endogenously produced compounds such
as arachidonic acid metabolites, bilirubin,
cAMP, as well as tryptophan catabolites
such as tryptamine and 6-formylindolo
[3,2-b]carbazole (FICZ) are ligands of the
promiscuous AHR with potential relev-
ance both in physiological conditions and
cancer. In addition the immediate trypto-
phan (Trp) metabolite kynurenine (Kyn),
which is known to suppress antigen-
specific T-cell responses,
5 has been shown
to promote Treg differentiation via the
AHR.
6 However, whether these endo-
genous AHR ligands are produced in the
tissue microenvironment in amounts suf-
ficient to modulate immune responses had
not been shown to date. We have shown
that malignant glioma produce enough
Kyn from Trp to activate the AHR due
to a high constitutive activity of the
tryptophan-2,3-dioxygenase (TDO).
7 The
fact that TDO is responsible for Trp
metabolism in glioma was surprising as
its expression was previously thought to
be restricted to liver and neural cells and
as Trp catabolism in tumors had been
attributed to the enzymatic activity of
indoleamine-2,3-dioxygenase 1 (IDO1).
In fact, IDO1 is a key factor of the
tumor microenvironment suppressing
tumor immunity and promoting immune
evasion.
8,9 Our study suggest that tumor-
derived TDO is equally capable of
inducing immunosuppression as TDO-
expressing tumors resist immune-mediated
lysis and as strong TDO-expression in
human tumors is associated with fewer
infiltrating CD8+ T cells.
7 Two observa-
tions suggest that the AHR is mediat-
ing immunosuppression by TDO: (A)
Immune infiltration in TDO-expressing
tumors is restored in AHR-deficient mice;
and (B) AHR target genes such as the
TCDD-inducible poly [ADP-ribose]
polymerase (TIPARP), which has high
homology to TIL, a gene isolated from
tumor-infiltrating T cells,
10 are specifically
induced in immune cells infiltrating
TDO-positive but not TDO-negative
tumors.
7 Kyn is not a low affinity AHR
ligand. In radioligand assays the apparent
Kd was around 4 mM, the EC50 was
12.3 mM in enzymatic assays and 36.6 mM
in reporter assays. Since the mean tissue
concentration in TDO-expressing tumors
was 37 mM and since concentrations of up
to 60 mM were measured in the cell
culture supernatant of TDO-expressing
tumors Kyn-production in gliomas is
within a relevant range to activate the
AHR.
7 There are three central questions
that need to be addressed: (1) Is the
AHR the sole mediator of immunosup-
pressive Trp catabolism in the tumor
microenvironment, (2) what are the cel-
lular determinants of AHR-mediated
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and (3) what are the molecular targets? As
direct experimental evidence is currently
lacking one can only speculate on the
answers: 1) Depletion of Trp from the
micromilieu may be sufficient to induce
immunosuppression by activating the
integrated stress response in T cells. Possi-
bly, the net effect is a combination of
both, depletion of Trp and accumulation
of Kyn. 2) Kyn may act on the AHR on T
cells and dendritic cell, two key com-
ponents of tumor immunity.
4,6 Based on
the observations in autoimmune disease
models it is tempting to speculate that
TDO-derived Kyn induces Treg cells that
in turn suppress tumor-specific CD8+
T cells. It may, however, be equally
possible that Kyn acts directly on tumor-
specific CD8+ T cells or via generating
tolerogenic DC in an AHR-dependent
fashion. These questions can only be
answered using conditional knockout
mice that are already available. 3) While
TIPARP may be an intriguing candidate
target gene of the AHR in T cells, we
found broad induction of AHR-dependent
genes by Kyn that are related to immune
responses for instance interleukin-1beta
(IL-1b), IL-6 or chemokines such as
CCL2. The contribution of these AHR
target genes in the context of tumor
immunity will have to be determined.
What’s clear from our data is that the
AHR represents a novel therapeutic
target in glioma and possibly other types
of cancer to revert local immunosup-
pression in the tumor microenviron-
ment possibly as an adjunct to active
immunotherapies.
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Figure1. Tumor cells (gray) with active tryptophan-2,3-dioxygenase (TDO) convert tryptophan (Trp)
to kynurenine (Kyn), which is secreted in the extracellular space and binds the aryl hydrocarbon
receptor (AHR) in neighboring immune cells (red), where it induces its translocation into the
nucleus. The AHR binds dioxin responsive elements (DRE) in the promoter of its target genes,
suppressing proliferation and function of immune cells thus suppressing tumor immune responses.
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